Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Pri0r1ty reports strong start to new financial year

(Sharecast News) - Pri0r1ty Intelligence Group said in an update on Friday that it had made a strong start to the 2026 financial year, reporting contracted revenue of more than £0.5m only three months into the period, already exceeding the group's total revenue for the whole of the 2025 period. The AIM-traded group, whose financial year started on 1 October, said the early momentum reflected the rollout of its proprietary AI products Advisor, Fan Sonar, Vox and Compass ID, which were designed to help small and medium-sized enterprises capture, enrich and deploy audience data within operational workflows to drive growth.

Pri0r1ty said it had secured new contracts with clients including World Aquatics, Untamd and Love Mondays, while expanding product usage among existing customers such as Aston Villa FC, Leukaemia Care, United Stand, the Racecourse Association and Great British Racing.

The company said its technology was now being rolled out across all 58 UK racecourses through its work with the Racecourse Association.

It currently had more than 100 paying users across its platforms and was targeting 500 paying platform users by the end of the 2026 financial year, which it said would establish a base for broader marketing across the UK SME sector.

Pri0r1ty estimated there were more than five million SMEs in the UK investing in customer data solutions.

The company said it was scaling its SME customer base by focusing on sector-specific verticals through its three specialist operating businesses.

Halfspace focuses on data-led marketing and growth solutions in the sports sector, Metr1c operates in brand partnerships and growth solutions across music, entertainment and lifestyle, while the Pri0r1ty platform provides AI-driven software-as-a-service tools to help SMEs maximise the value of their first-party data and improve operational efficiency.

"At a little over three months into the financial year, we have already contracted revenue that exceeds the prior full financial year," said Rory Maxwell, chief executive of Pri0r1ty.

"This is an encouraging position from which to scale users on our platform deploying our AI products.

"The developing revenue pipeline is evidence that the diversified scope of the company's model is working, combining AI products to scale data capture and enrichment for clients, alongside outcome-focused enterprise consultancy services to integrate data into operational workflows that deliver growth for clients."

Maxwell said the group planned to continue building momentum by expanding product capability and accelerating customer acquisition through its sector-specialist operating companies as it looked to grow market share across the SME sector.

At 1129 GMT, shares in Pri0r1ty Intelligence Group were flat at 1.9p.

Reporting by Josh White for Sharecast.com.

Share this article

Related Sharecast Articles

Jefferies upgrades Dunelm to 'buy', says recent de-rating was overdone
(Sharecast News) - Jefferies upgraded Dunelm on Monday to 'buy' from 'hold' as it said the recent de-rating was overdone.
Jangada agrees to acquire Brazil's Molly Gold project
(Sharecast News) - Jangada Mines said on Monday that it has signed a letter of intent to secure an exclusive option to acquire 100% of the Molly Gold Project in the Tapajós region of Pará State, Brazil, as it looked to build a portfolio of high-grade gold assets in the country.
Quantum Helium de-risks Sagebrush production tests with new data
(Sharecast News) - AIM-listed Quantum Helium has revealed that a seismic review at its Sagebrush Helium Project in Colorado has materially de-risked the planned extended production test at the first well.
JP Morgan raises target price on GSK
(Sharecast News) - Analysts at JP Morgan raised their target price on drugmaker GSK to £22.50 on Monday on improving investor perception.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.